SightfileU.S. market data from official filings

Companies › IMMX

Immix Biopharma Inc (IMMX)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001873835 · EDGAR filings · Updated 2026-07-20

Immix Biopharma Inc (IMMX) has reported institutional ownership of 51.1%, with 77 institutional managers holding positions valued at $246.6M per the latest 13F reporting period. SEC filings include an active substantial-doubt (going concern) disclosure per the filings.

Institutional ownership
51.1%
Institutional managers
77
Reported 13F value
$246.6M
Insider activity
7 trans.
$30.3K net buying
Data flags
1 active
from SEC filings

Latest updates

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, Immix Biopharma Inc has 77 institutional holders and institutional ownership of 51.1%.

Insider activity

Insiders reported 7 transactions (6 buys, 0 sells) across 9 reporting insiders, with a net reported value of $30.3K.

Data flags from SEC filings

Active substantial-doubt (going concern) disclosure per the filings, most recently filed 2025-11-07 (recurring since 2025-08-08) — source filing. The authoritative details are those stated in the filing itself.

Related companies

SURROZEN INC (SRZN) · PALISADE BIO INC (PALI) · EIKON THERAPEUTICS INC (EIKN) · AGOMAB THERAPEUTICS NV (AGMB) · PROTARA THERAPEUTICS INC (TARA) · LYELL IMMUNOPHARMA INC (LYEL)

See full history, cross-references and alerts on Sightfile
Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-20.